Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2A Study of Hantaan and Puumala Virus DNA Vaccines
NCT04333459Phase 2Completed
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Hantaan virus DNA vaccine and Puumala virus DNA vaccine in Hantavirus infection and Puumala virus nephropathy (NE) (4 arms), sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Proportion of subjects in Group 1 that achieve seroconversion at Day 197 and Proportion of subjects in Group 3 that achieve seroconversion at Day 197. Started Aug 2021; status: completed.
02
Drugs
Hantaan virus DNA vaccinePuumala virus DNA vaccine
03
Conditions
Hantavirus infectionPuumala virus nephropathy (NE)
Beyond the preview
Go deeper on NCT04333459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333459.